Last reviewed · How we verify
A3384
At a glance
| Generic name | A3384 |
|---|---|
| Sponsor | Albireo |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Double-blind, Randomised Study of A3384 in BAM/BAD (PHASE2)
- A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- A3384 CI brief — competitive landscape report
- A3384 updates RSS · CI watch RSS
- Albireo portfolio CI